可溶性鸟苷酸环化酶激动剂在心血管方面的研究进展  

New research progress of soluble guanylate cyclase agonist in cardiovascular system

作　　者：朱友琦 胡威 白明[1,2,3] ZHU You-qi;HU Wei;BAI Ming(First Clinical Medical College,Lanzhou University,Lanzhou,730000,Gansu,China;Department of Cardiology,First Hospital of Lanzhou University,Lanzhou,730000,Gansu,China;Heart Center,First Hospital of Lanzhou University,Lanzhou,730000,Gansu,China)

机构地区：[1]兰州大学第一临床医学院,甘肃兰州730000 [2]兰州大学第一医院心内科,甘肃兰州730000 [3]兰州大学第一医院心脏中心,甘肃兰州730000

出　　处：《心脏杂志》2023年第5期592-596,共5页Chinese Heart Journal

基　　金：兰州市人才创新创业项目(2021-RC-91);甘肃省国际科技合作基地(甘科外{2018}3号);甘肃省科技计划项目重点研发计划(21YF5FA118)。

摘　　要：心血管疾病成为全球首要疾病负担,是目前最为严重的公共卫生问题。可溶性鸟苷酸环化酶激动剂在一氧化氮-可溶性鸟苷酸环化酶-环磷酸鸟苷信号通路调节心血管系统方面起着重要作用。越来越多的研究显示,可溶性鸟苷酸环化酶激动剂在心肌细胞肥厚、心肌重构及心肌缺血再灌注损伤等方面具有保护作用,其潜在的作用机制还有待深入探索。可溶性鸟苷酸环化酶激动剂可减少心血管死亡事件和心衰再住院风险。本文主要针对可溶性鸟苷酸环化酶激动剂在高血压、肺动脉高压及心力衰竭等心血管疾病方面的保护机制进行探讨,以期加深对可溶性鸟苷酸环化酶激动剂的认识。Cardiovascular disease has become the global leading burden of disease and it is currently the most serious public health problem.Soluble guanylate cyclase agonists play an important role in regulating the cardiovascular system in the nitric oxide-soluble guanylate cyclase-cyclic guanosine phosphate signaling pathway.More and more studies have shown that soluble guanylate cyclase agonists have protective effects on cardiomyocyte hypertrophy,myocardial remodeling and myocardial ischemiareperfusion injury,and its potential mechanism remains to be explored in depth.Soluble guanylate cyclase agonists can reduce cardiovascular deaths and re-hospitalization for heart failure.This article focuses on the protective mechanism of soluble guanylate cyclase agonists in cardiovascular diseases such as hypertension,pulmonary hypertension and heart failure,with the aim of deepening the understanding of soluble guanylate cyclase agonists.

关 键 词：可溶性鸟苷酸环化酶 sGC激动剂 信号通路 心血管疾病 

分 类 号：R541.6[医药卫生—心血管疾病]